**ARUP** Laboratories
500 Chipeta Way – Salt Lake City, UT 84108
(800)522-2787 - www.aruplab.com
Julio C. Delgado, M.D. M.S., Director of Laboratories

*****Example Report*****

Patient Age/Gender: Unknown Male
Printed: 14-Dec-18 13:50:00

| Procedure | Result | Units | Ref Interval | Accession | Collected | Received | Reported/ Verified |
|---|---|---|---|---|---|---|---|
| EGFR FISH Result | Not Amplified f | | | 18-346-900185 | 12-Dec-18 10:28:00 | 12-Dec-18 10:28:00 | 14-Dec-18 13:43:55 |
| EGFR/CEP7 FISH Ratio | 1.0 | | | 18-346-900185 | 12-Dec-18 10:28:00 | 12-Dec-18 10:28:00 | 14-Dec-18 13:43:55 |
| Average EGFR Signal Number per Cell | 2.0 | | | 18-346-900185 | 12-Dec-18 10:28:00 | 12-Dec-18 10:28:00 | 14-Dec-18 13:43:55 |
| Average CEP7 Signal Number per Cell | 2.0 | | | 18-346-900185 | 12-Dec-18 10:28:00 | 12-Dec-18 10:28:00 | 14-Dec-18 13:43:55 |
| EGFR FISH Reference Number | S18-123 | | | 18-346-900185 | 12-Dec-18 10:28:00 | 12-Dec-18 10:28:00 | 14-Dec-18 13:43:55 |
| EGFR FISH Source | Tissue | | | 18-346-900185 | 12-Dec-18 10:28:00 | 12-Dec-18 10:28:00 | 14-Dec-18 13:43:55 |
| Total Cell Count | 50 | | | 18-346-900185 | 12-Dec-18 10:28:00 | 12-Dec-18 10:28:00 | 14-Dec-18 13:43:55 |
| Scoring Method | Manual | | | 18-346-900185 | 12-Dec-18 10:28:00 | 12-Dec-18 10:28:00 | 14-Dec-18 13:43:55 |

12-Dec-18 10:28:00 EGFR FISH Result:

This result has been reviewed and approved by Larissa V. Furtado, M.D. Controls performed as expected.

12-Dec-18 10:28:00 EGFR FISH Result:
METHODOLOGY AND INTERPRETIVE DATA:

Fluorescence in situ hybridization (FISH) analysis for EGFR gene amplification was performed on a section from a paraffin embedded tissue block using differentially labeled fluorescent probes targeting the EGFR gene and the chromosome 7 centromere (CEP 7) (Abbott Molecular). Cells were evaluated from regions of tumor identified on histopathologic review of a matching hematoxylin and eosin stained section. Controls performed appropriately.

EGFR gene amplification (EGFR/CEP7 ratio of 2.0 or greater) is observed in a variety of tumor types. In gliomas, EGFR amplification is associated with higher grade tumors, especially primary glioblastomas. EGFR amplification status has been correlated with a worse outcome in anaplastic astrocytoma, and may also be used as a prognostic marker or to predict tumor response to targeted therapy in certain other tumor types.

Reference:

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Figarella-Branger D, Perry A, Reifenberger G, von Deimling A, Eds. WHO Classification of Tumours of the Central Nervous System, Revised 4th Edition. Lyon, France: International Agency for Research on Cancer, 2016.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement A: aruplab.com/CS.

***** Abnormal, **#** = Corrected, **C** = Critical, **f** = Footnote, **H** = High, **L** = Low, **t** = Interpretive Text, **@** = Reference Lab